Literature DB >> 993482

Circulating basophils in normal subjects and in subjects with hay fever.

S R Hirsch, J H Kalbfleisch.   

Abstract

The relationship of hay fever symptoms and changes in the number of circulating basophils was studied in 12 subjects clinically sensitive only to ragweed and in 10 nonatopic subjects before, during, and after the ragweed season. Total white blood counts, absolute basophil counts, and symptom scores were recorded twice weekly from mid-June through October, 1974, and compared with the ragweed pollen count. The results indicated that the absolute and relative number of basophils were significantly elevated (p less than 0.001) in the hay fever group when symptoms occurred. As the symptom score of the allergic group increased during the ragweed season, the number of basophils also increased, only to decrease to control values when symptoms subsided. The basophil counts of the atopic group were significantly higher than those of the nonatopic group during the control periods. The nonatopic group also showed a significant elevation of basophils during the ragweed season, but to a much lesser extent than the atopic group. It is concluded that: (1) subjects with symptomatic hay fever have a significantly elevated absolute and relative basophil count which correlates with the exacerbation and remission of symptoms; (2) nonatopic subjects also have a small but significant elevation of basophils during the ragweed season; and (3) the elevation of basophils in the atopic group during symptoms is significantly greater than in the nonatopic group during the ragweed season.

Entities:  

Mesh:

Year:  1976        PMID: 993482     DOI: 10.1016/0091-6749(76)90179-2

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  5 in total

1.  The management of hay fever in general practice.

Authors:  R W Harland
Journal:  J R Coll Gen Pract       Date:  1979-05

Review 2.  Late asthmatic responses: inquiry into mechanisms and significance.

Authors:  W J Metzger; G W Hunninghake; H B Richerson
Journal:  Clin Rev Allergy       Date:  1985-05

3.  First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases.

Authors:  Eric Helmer; Mark Watling; Emma Jones; Dominique Tytgat; Mark Jones; Rodger Allen; Andrew Payne; Annelize Koch; Eugene Healy
Journal:  Eur J Clin Pharmacol       Date:  2017-02-04       Impact factor: 2.953

Review 4.  Behind the scenes with basophils: an emerging therapeutic target.

Authors:  Hemali Shah; Stephanie Eisenbarth; Christopher A Tormey; Alexa J Siddon
Journal:  Immunother Adv       Date:  2021-05-19

5.  Blood basophils in lung cancer.

Authors:  H M Anthony
Journal:  Br J Cancer       Date:  1982-02       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.